Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin

Diabetes Care

Volumn 33, Issue 5, 2010, Pages 951-957

  DeFronzo, Ralph A ^a   Triplitt, Curtis ^a   Qu, Yongming ^b   Lewis, Michelle S ^c   Maggs, David ^d   Glass, Leonard C ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c US Medical Division   (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; EXENDIN 4; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOOT EDEMA; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; AGED; DRUG COMBINATION; DRUG EFFECT; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; SECRETION;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VENOMS; WEIGHT GAIN;

EID: 77954897689     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1521     Document Type: Article

References (25)

1. Reaven GM. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
2. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
3. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803 (Pubitemid 34970933)
4. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871-E883
5. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 (Pubitemid 44903747)
6. Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:200-206 (Pubitemid 38183882)
7. Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005;54:3148-3153 (Pubitemid 43334368)
8. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303 (Pubitemid 29383658)
9. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001;44:2210-2219 (Pubitemid 34015474)
10. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003;52:1943-1950 (Pubitemid 36919785)
11. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301 (Pubitemid 121000706)
12. Vilsbøll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull 2004;51:364-370 (Pubitemid 41519091)
13. Amylin Pharmaceuticals. Byetta (exenatide) injection [package insert]. San Diego, CA. 2008 ref type: generic
14. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282-1290 (Pubitemid 36121100)
15. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23:807-812 (Pubitemid 30414198)
16. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223 (Pubitemid 9249478)
17. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
18. Defronzo RA. Banting Lecture 2009: From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
19. DeFronzo RA. Lilly Lecture 1987: The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687
20. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-39
21. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55:1430-1435
22. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794
23. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
24. Jallut D, Golay A, Munger R, Frascarolo P, Schutz Y, Jéquier E, Felber JP. Impaired glucose tolerance and diabetes in obesity: a 6-year follow-up study of glucose metabolism. Metabolism 1990;39:1068-1075
25. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetes patients: a randomized, controlled trial. Diabetes Care 2009;32:762-768